When was LABORATOIRE X.O acquired by NOVALPINA CAPITAL?

LABORATOIRE X.O was acquired by NOVALPINA CAPITAL in 2020.

What was the revenue of LABORATOIRE X.O at the time of the deal?

The revenue of LABORATOIRE X.O at the time of the deal is estimated to be in the range of 25M - 50M EUR.

How is the data for the LABORATOIRE X.O acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LABORATOIRE X.O deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.unquote.com/france/official-record/3021741/novalpina-buys-majority-stake-in-laboratoire-xo

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaLABORATOIRE X.O

11/2020

LABORATOIRE X.O acquired by NOVALPINA CAPITAL

FRANCE Life Sciences / Pharma & Biotech / Generics / Labs REV 25M - 50M EUR

Context

Novalpina Capital made its first French investment by acquiring a controlling stake in Laboratoire X.O. The deal values the company at over EUR300M, supported by a unitranche debt facility from Ares Management. Novalpina has also reserved EUR100M for future acquisitions. The objective is to triple revenue within five years by acquiring more drug portfolios and expanding the group's international footprint beyond France and Francophone Africa.

LABORATOIRE X.O, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2015, Laboratoire X.O is a specialty pharmaceutical company focused on acquiring and revitalizing mature drug brands (Legacy Brands) from "Big Pharma." It operates an asset-light model, outsourcing production while managing 21 Market Authorizations (MA). Its portfolio includes prescription drugs and a growing Over-The-Counter (OTC) division, with key brands like Prexidine (mouthwash).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Other operations with LABORATOIRE X.O

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
10/2022	STANLEY CAPITAL PARTNERS	LABORATOIRE X.O	FRANCE	Generics / Labs

REFERENCES

Revenue range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LABORATOIRE X.O by NOVALPINA CAPITAL are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.